Degulis v. LXR Biotechnology, Inc.

176 F.R.D. 123, 1997 U.S. Dist. LEXIS 18490, 1997 WL 725912
CourtDistrict Court, S.D. New York
DecidedNovember 20, 1997
DocketNos. 95 CIV. 4204 RWS, 95 CIV. 6422 RWS, 95 CIV. 4299 RWS, 95 CIV. 7215 RWS, 95 CIV. 4298 RWS
StatusPublished
Cited by7 cases

This text of 176 F.R.D. 123 (Degulis v. LXR Biotechnology, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Degulis v. LXR Biotechnology, Inc., 176 F.R.D. 123, 1997 U.S. Dist. LEXIS 18490, 1997 WL 725912 (S.D.N.Y. 1997).

Opinion

OPINION

SWEET, District Judge.

By letter motions defendants Ariad Pharmaceuticals, Inc., Harvey J. Berger, and Edgar Haber (collectively, “Ariad”), and LXR Biotechnology, Inc., L. Scott Minick, Mark J. Tomei, James D. Coombes and Christopher S. Henney (collectively “LXR” and together with Ariad, the “Defendants”) seek certain brokerage and investment records of plaintiff Joseph Degulis (“Degulis”) in this securities action in which class certification is sought. For the reasons set forth below, the motions are granted.

The Parties

Degulis purchased securities of Ariad and LXR in their initial public offerings (“IPOs”) on May 20,1994 and May 6,1994, respectively.

Ariad is a Delaware corporation having its principal place of business in Cambridge, Massachusetts.

LXR is a Delaware corporation having its principal place of business in Richmond, California.

Mr. Minick, Mr. Tomei, Mr. Coombes and Mr. Henney were officers and/or directors of LXR at the time of the LXR IPO, signed the 1994 LXR Registration Statement, and owned stock at the time of the LXR IPO.

Mr. Berger is Chairman, President and CEO of Ariad. Mr. Haber, an outside director, is Vice Chairman of the Ariad board. Both hold stock in Ariad and signed the 1994 Ariad Registration Statement.

Prior Proceedings

These actions alleging securities and common law fraud, filed on June 8,1995, are two of six actions arising out of the IPOs of various start-up biotechnology companies in which D. Blech & Co. (“Blech”) was the underwriter and its principal, David Blech, was involved. The six actions are In re Blech Securities Litigation, 94 Civ. 7696(RWS), Degulis v. Ariad Pharmaceuticals, Inc., 95 Civ. 4298(RWS); Degulis v. LXR Biotechnology, Inc., 95 Civ. 4204(RWS); Kozloski v. Intelligent Surgical Lasers, 95 Civ. 4299(RWS); Weiss v. Blech, 95 Civ. 6422(RWS); and Katz v. Blech, 95 Civ. 6423(RWS). In re Blech is itself a consolida[125]*125tion of four related actions: Bronson v. Blech, 94 Civ. 7959(RWS), Garfinkel v. Blech, 94 Civ. 7873(RWS), Libauer v. Blech, 94 Civ. 7696(RWS), and Mays v. D. Blech & Co., 94 Civ. 7704(RWS). Discovery has been consolidated in these cases.

The factual and procedural background of these related cases is set forth in the prior opinions of this Court, familiarity with which is assumed. See Weiss v. Blech, No. 95 Civ. 6422, 1997 WL 458678 (S.D.N.Y. Aug. 11, 1997); Degulis v. LXR Biotechnology, Inc., No. 95 Civ. 4202, 1997 WL 20832 (S.D.N.Y. Jan. 21, 1997); Degulis v. LXR Biotechnology, Inc., 928 F.Supp. 1301 (S.D.N.Y.1996); see also In re Blech Secs. Litig., 961 F.Supp. 569 (S.D.N.Y.1997); In re Blech Secs. Litig., No. 94 Civ. 7696, 1997 WL 20833 (S.D.N.Y. Jan. 21, 1997); In re Blech Secs. Litig., 928 F.Supp. 1279 (S.D.N.Y.1996).

This dispute arises out of Defendants’ deposition notice and document request to Degulis served on April 22, 1997. Specifically, Degulis has refused to produce the documents identified in request numbers 16 and 17, which seek: “[a]ll documents concerning applications to establish brokerage accounts or other facilities for the purchase and sale of securities or commodities” and “[mjonthly account statements for any securities or commodities account maintained by, or on behalf of, Plaintiff during the period January 1, 1992 to present.”

In response to this document request, Degulis has produced only those records relating to securities underwritten by Blech.

On August 15,1997, Defendant’s requested by letter motion to compel production of the documents. The motion was heard and considered submitted on September 10, 1997.

Discussion

I. Legal Standard For Discovery

Rule 26(b)(1) of the Federal Rules of Civil Procedure provides, in part: “Parties may obtain discovery regarding any matter, not privileged, which is relevant to the subject matter involved in the pending action. ... The information sought need not be admissible at trial if the information sought appears reasonably calculated to lead to the discovery of admissible evidence.” The discovery rules are to be given a broad and liberal construction to effectuate their purpose of ensuring that civil trials are not conducted in the dark. See Schlagenhauf v. Holder, 379 U.S. 104, 114-15, 85 S.Ct. 234, 240-41, 13 L.Ed.2d 152 (1964); see also Oppenheimer Fund, Inc. v. Sanders, 437 U.S. 340, 351, 98 S.Ct. 2380, 2389, 57 L.Ed.2d 253 (1978) (standard “has been construed broadly to encompass any matter that bears on, or that reasonably could lead to other matter that could bear on, any issue that is or may be in the case”). Moreover, the concept of relevance for discovery purposes is not limited by considerations of evidentiary admissibility, but rather is broad enough to afford parties liberal access to evidence in advance of trial. See Quaker Chair Corp. v. Litton Business Sys., Inc., 71 F.R.D. 527, 530-31 (S.D.N.Y.1976). While the discovery rules are broad, they do not permit discovery of matters that are not relevant to issues in the case or calculated to lead to relevant and admissible evidence.

II. The Requested Documents are Discoverable

Defendants contend that the investment documents identified in the document request may shed light on Degulis’ investment sophistication and strategy, and that this information is relevant to the issue of whether Degulis relied upon Defendants’ alleged misrepresentations or omissions, when purchasing the stock in the IPOs.

The Ariad and LXR complaints allege violations of, inter alia, (1) Section 10(b) of the Securities Exchange Act of 1934, 48 Stat. 891, as amended, 15 U.S.C. § 78j(b) and SEC Rule 10b-5, 17 C.F.R. § 240.10b-5 (the “10b-5 claim”), and (2) common-law fraud and deceit. See Ariad Complaint, Counts III, IV; LXR Complaint, Counts III, IV. Moreover, the factual allegations specifically contend that Degulis “relied upon ... the statements disseminated by defendants during the Class Period” and that he purchased the securities [126]*126“[i]n reliance upon [] misrepresentations.” See Ariad Complaint ¶¶ 62, 69.

To prove the common law fraud claim, Degulis must show that he relied on the Defendants’ alleged misrepresentations or omissions. See Bridgestone/Firestone, Inc. v. Recovery Credit Services, Inc., 98 F.3d 13, 19 (2d Cir.1996) (reliance an element of fraud under New York common law); Banque Arabe et Internationale D’Investissement v. Maryland Nat’l Bank, 57 F.3d 146, 153 (2d Cir.1995) (same).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Weilburg v. Rodgers
N.D. New York, 2023
Santos v. Schroeder
N.D. New York, 2022
Berwecky v. Bear, Stearns & Co.
197 F.R.D. 65 (S.D. New York, 2000)
Weikel v. Tower Semiconductor Ltd.
183 F.R.D. 377 (D. New Jersey, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
176 F.R.D. 123, 1997 U.S. Dist. LEXIS 18490, 1997 WL 725912, Counsel Stack Legal Research, https://law.counselstack.com/opinion/degulis-v-lxr-biotechnology-inc-nysd-1997.